147 related articles for article (PubMed ID: 34638492)
21. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
[TBL] [Abstract][Full Text] [Related]
22. A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action.
Mohan N; Luo X; Shen Y; Olson Z; Agrawal A; Endo Y; Rotstein DS; Pelosof LC; Wu WJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804477
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
24. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
Shao F; Sun H; Deng CX
Oncotarget; 2017 Sep; 8(42):73329-73344. PubMed ID: 29069872
[TBL] [Abstract][Full Text] [Related]
25. BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.
Shields S; Conroy E; O'Grady T; McGoldrick A; Connor K; Ward MP; Useckaite Z; Dempsey E; Reilly R; Fan Y; Chubb A; Matallanas DG; Kay EW; O'Connor D; McCann A; Gallagher WM; Coppinger JA
Oncotarget; 2018 Mar; 9(21):15673-15690. PubMed ID: 29644001
[TBL] [Abstract][Full Text] [Related]
26. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
27. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
28. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
29. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
30. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
31. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
[TBL] [Abstract][Full Text] [Related]
32. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.
Bao B; Mitrea C; Wijesinghe P; Marchetti L; Girsch E; Farr RL; Boerner JL; Mohammad R; Dyson G; Terlecky SR; Bollig-Fischer A
Sci Rep; 2017 Mar; 7():44125. PubMed ID: 28281569
[TBL] [Abstract][Full Text] [Related]
33. Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy.
Flashner-Abramson E; Vasudevan S; Adejumobi IA; Sonnenblick A; Kravchenko-Balasha N
Theranostics; 2019; 9(18):5149-5165. PubMed ID: 31410207
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression.
Guo L; Zheng J; Zhang J; Wang H; Shao G; Teng L
Oncol Rep; 2016 Aug; 36(2):729-36. PubMed ID: 27373987
[TBL] [Abstract][Full Text] [Related]
36. Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells.
Yin L; Qi XW; Liu XZ; Yang ZY; Cai RL; Cui HJ; Chen L; Yu SC
Oncol Lett; 2020 Jun; 19(6):3950-3958. PubMed ID: 32382339
[TBL] [Abstract][Full Text] [Related]
37. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
Lev S
Biochem Soc Trans; 2020 Apr; 48(2):657-665. PubMed ID: 32311020
[TBL] [Abstract][Full Text] [Related]
39. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]